EXCLUSIVE: BioRestorative Therapies Tells Benzinga 'Clinical data expected to be reviewed by independent data safety monitoring board (DSMB) as to initial safety dosing profile of BRTX-
100'
Portfolio Pulse from Benzinga Newsdesk
BioRestorative Therapies announced that clinical data for its BRTX-100 treatment is expected to be reviewed by an independent data safety monitoring board (DSMB) for initial safety dosing profile.
June 12, 2023 | 10:30 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
BioRestorative Therapies' BRTX-100 clinical data review by DSMB may impact the company's stock price in the short term.
The review of BRTX-100 clinical data by an independent data safety monitoring board (DSMB) is an important step in the development process of the treatment. A positive review may boost investor confidence in the company, while a negative review may have the opposite effect. However, the short-term impact on the stock price is uncertain as the market may have already priced in the expected review.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100